B8F Biofrontera

Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.

Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz® in Poland with medac GmbH Sp. z o.o.

Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement with medac GmbH Sp. z o.o., the Polish branch of medac Gesellschaft für klinische Spezialpräparate mbH, for the marketing of Ameluz® and BF-RhodoLED® in Poland.

Ameluz® has a centralized European drug approval which currently includes the treatment of mild and moderate actinic keratoses, field cancerization, photodynamic therapy with daylight, as well as nodular and superficial basal cell carcinoma. Ameluz® is used in combination with daylight or a red-light lamp, Biofrontera's BF-RhodoLED®.

The term sheet contains terms and conditions regarding the amount of the one-time upfront payment of around EUR 200,0000, the term of approximately 5 years, the transfer price for Ameluz® and BF-RhodoLED®, as well as local regulatory responsibilities in Poland.

medac Gesellschaft für klinische Spezialpräparate mbH is a global pharmaceutical company based in Germany, which has been specializing in the treatment and diagnosis of oncological, urological and autoimmune diseases. In Poland, the company has a leading sales structure in dermatology.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113

WKN: 604611

Contact: Biofrontera AG

Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

E-mail:

EN
13/03/2020

Underlying

B8FBiofrontera

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biofrontera

Free Trial
B8F BIOFRONTERA

Biofrontera AG: 1 director

A director at Biofrontera AG bought 40,000 shares at 1.276EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

02/10/23 February 10, 2023 1 EN
 PRESS RELEASE
Free
B8F BIOFRONTERA

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity ...

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative cos...

February 14, 2022 1 EN
 PRESS RELEASE
Free
B8F BIOFRONTERA

Biofrontera AG announces mediation results

Biofrontera AG announces mediation results Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major sh...

November 19, 2021 1 EN
 PRESS RELEASE
Free
B8F BIOFRONTERA

Biofrontera reports financial results for the third quarter and nine m...

Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021 Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 2...

November 17, 2021 1 EN
 PRESS RELEASE
Free
B8F BIOFRONTERA

Biofrontera AG announces initiation of clinical studies

Biofrontera AG announces initiation of clinical studies Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz® in the United States are being started with site initiations currently in progress, seven sites for the phase two study for the treatment of moderate- to- severe acne in adults as well as eight sites for the phase I safety study evaluating the safety of photodynamic therapy (PDT) with the si...

November 16, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch